Brower Piven Announces an Investigation of the Acquisition of Dialysis Corporation of America by U.S. Renal Care, Inc.

The law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Dialysis Corporation of America (“DCA”) (Nasdaq: DCAI) in connection with their actions in causing DCA to enter into a merger agreement with U.S. Renal Care, Inc. and its wholly-owned subsidiary Urchin Merger Sub, Inc. (“collectively, USRC”). The proposed transaction is valued at approximately $112 million.

Under the terms of the definitive merger agreement entered into by the parties, USRC, will commence a tender offer for all of the outstanding common shares of DCA for $11.25 per share in cash, followed by a merger to acquire all remaining outstanding DCA shares at the same cash price paid in the tender offer. USRC expects to commence the tender offer promptly, and anticipates the transaction will close in May 2010. The investigation concerns possible breaches of fiduciary duty and other violations of law related to approval of the transaction by DCA’s board of directors.

If you purchased and continue to own shares of Dialysis Corporation of America and would like to learn more about the investigation being conducted by Brower Piven, you may e-mail or call Brower Piven, who will, without obligation or cost to you, attempt to answer your questions. You may contact Brower Piven by email at [e-mail], by calling 410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and other class action cases of over 40 years.